Immediate Impact
54 standout
Citing Papers
Colorectal cancer
2024 Standout
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
Works of D. Errante being referenced
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen
2012
The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer
2006
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| D. Errante | 1069 | 752 | 242 | 267 | 45 | 1.4k | |
| D Schlaifer | 900 | 792 | 245 | 213 | 53 | 1.6k | |
| Milayna Subar | 1041 | 687 | 266 | 141 | 32 | 1.6k | |
| Edgar M. Moran | 1060 | 888 | 407 | 120 | 54 | 2.1k | |
| Michael P. Corder | 494 | 581 | 303 | 151 | 43 | 1.7k | |
| Pak‐Kwan Hui | 721 | 790 | 200 | 131 | 46 | 1.8k | |
| R. Arranz | 852 | 705 | 257 | 141 | 41 | 1.5k | |
| Tanin Intragumtornchai | 703 | 816 | 183 | 155 | 67 | 1.5k | |
| Graziella Pinotti | 966 | 931 | 238 | 276 | 62 | 1.9k | |
| Samir Dalia | 549 | 484 | 195 | 68 | 81 | 1.2k | |
| Christoph Losem | 1040 | 1324 | 873 | 225 | 46 | 1.8k |
All Works
Loading papers...